For the first time in Florida, a 63-year-old man has received a groundbreaking gene therapy implant designed to slow vision loss from a rare retinal disease. The surgery, performed in December 2025 at Bascom Palmer Eye Institute, marks a major step forward for patients with macular telangiectasia type 2, or MacTel, a condition that gradually destroys central vision.
The implant, called Encelto (revakinagene taroretcel-lwey), is the first FDA-approved treatment specifically for MacTel. It works by delivering a steady supply of a protective protein called ciliary neurotrophic factor, or CNTF, directly into the eye. The tiny device, about the size of a grain of rice, is surgically placed behind the lens and contains roughly 300,000 lab-engineered human cells that continuously produce the protein. Unlike standard gene therapy, it does not use the patient's own cells, which lowers the risk of side effects. If needed, the implant can be removed entirely.
MacTel affects about one in 10,000 people and typically leaves patients with vision around 20/60, making daily tasks like reading or driving extremely difficult. The implant is approved for use at any stage of the disease and is expected to slow the rate of vision loss by about half. The patient received the implant in just one eye initially, allowing doctors to monitor how his body tolerates it before considering treatment for the other eye.
Decades of Research Lead to a New Approach
The journey to this treatment began in the 1990s, when researchers discovered that CNTF could help preserve vital retinal cells. A major challenge was that the protein breaks down quickly, requiring daily injections into the eye. The solution came through genetic engineering: creating a tiny implant that releases CNTF steadily over time. The cells inside the implant feed on the eye's natural fluids and release the protein into the vitreous cavity, where it travels to the retina. Its primary effect is on Müller cells, which support the photoreceptors essential for sight. By keeping these support cells alive, the implant also protects the photoreceptors themselves.
Doctors are already exploring whether similar implants could help with other retinal diseases. A recent study involving glaucoma patients showed some benefit in slowing disease progression. However, MacTel has had no other approved treatments, making this breakthrough especially significant for those affected.
Looking ahead, researchers hope this success will accelerate development of similar therapies for other conditions. The path from discovery to treatment was anything but straight, but it demonstrates how persistent collaboration between clinicians and scientists can turn a rare disease diagnosis into a treatable condition. For patients with MacTel, the future is suddenly brighter.